Maravai LifeSciences Files 8-K Report

TL;DR

MRVI filed an 8-K for 'Other Events' on Dec 18. Details TBD.

AI Summary

On December 18, 2024, Maravai LifeSciences Holdings, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Maravai LifeSciences has reported a material event to the SEC, which could be significant for investors monitoring the company's activities.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not contain specific negative or positive financial information in the provided text.

Key Players & Entities

• MARAVAI LIFESCIENCES HOLDINGS, INC. (company) — Registrant
• December 18, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — which registered Class A Common Stock, $0.01 par value MRVI The Nasdaq Stock Market
• $228 million — luntarily pre-paid, using cash on hand, $228 million of aggregate principal amount of the ou
• $300 million — ng under the Term Loan is approximately $300 million. There were no prepayment penalties ass
• $167 million — of principal. As of the date hereof, $167 million in aggregate borrowing capacity remaine

Filing Documents

• mrvi-20241218.htm (8-K) — 27KB
• 0001823239-24-000133.txt ( ) — 150KB
• mrvi-20241218.xsd (EX-101.SCH) — 2KB
• mrvi-20241218_lab.xml (EX-101.LAB) — 22KB
• mrvi-20241218_pre.xml (EX-101.PRE) — 13KB
• mrvi-20241218_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On December 18, 2024, Maravai Intermediate Holdings, LLC ("Maravai Intermediate"), a subsidiary of Maravai LifeSciences Holdings, Inc., voluntarily pre-paid, using cash on hand, $228 million of aggregate principal amount of the outstanding term loan (the "Term Loan") provided under the previously disclosed Credit Agreement, dated as of October 19, 2020, among Maravai Intermediate, Cygnus Technologies, LLC ("Cygnus"), TriLink Biotechnologies, LLC ("TriLink" and together with Maravai Intermediate and Cygnus, the "Borrowers"), Maravai TopCo Holdings, LLC, each lender from time to time party thereto, and Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent (as amended, the "Credit Agreement"). After giving effect to this prepayment of principal, the aggregate remaining principal balance outstanding under the Term Loan is approximately $300 million. There were no prepayment penalties associated with this prepayment of principal. As of the date hereof, $167 million in aggregate borrowing capacity remained available to the Borrowers under the revolving credit facility provided under the Credit Agreement.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARAVAI LIFESCIENCES HOLDINGS, INC. Date: December 18, 2024 By: /s/ Kevin M. Herde Name: Kevin M. Herde Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR